IFM Investors Pty Ltd Has $125.79 Million Stake in Eli Lilly and Company $LLY

Key Points

• IFM Investors Pty Ltd decreased its stake in Eli Lilly to approximately $125.79 million, owning 152,300 shares, which constitutes 1.4% of their portfolio.
• CEO David A. Ricks purchased 1,632 shares of Eli Lilly at an average price of $644.77, increasing his ownership to 546,601 shares, valued at approximately $352.43 million.
• Eli Lilly reported a net revenue of $15.56 billion for the recent quarter, surpassing analysts' expectations of $14.40 billion, with a significant year-over-year growth of 37.6%.

IFM Investors Pty Ltd decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 152,300 shares of the company's stock after selling 1,216 shares during the quarter. Eli Lilly and Company makes up approximately 1.4% of IFM Investors Pty Ltd's portfolio, making the stock its 12th biggest position. IFM Investors Pty Ltd's holdings in Eli Lilly and Company were worth $125,786,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Duquesne Family Office LLC raised its position in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Corient IA LLC bought a new position in Eli Lilly and Company during the 1st quarter worth $570,000. LS Investment Advisors LLC raised its position in Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the last quarter. Cutter Capital Management LP bought a new position in shares of Eli Lilly and Company in the 1st quarter worth about $14,866,000. Finally, Prism Advisors Inc. bought a new position in shares of Eli Lilly and Company in the 1st quarter worth about $207,000. 82.53% of the stock is owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $749.99 on Wednesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $942.35. The stock's 50 day moving average price is $742.49 and its 200-day moving average price is $779.42. The company has a market capitalization of $709.84 billion, a PE ratio of 49.02, a PEG ratio of 1.03 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the business earned $3.92 EPS. The company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. UBS Group lowered their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Daiwa America lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price target for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $950.17.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.